NeOnc Technologies获得美国食品药品监督管理局(FDA)授权,将推进Neo212的二期临床试验。Neo212是一款首创的口服化学共轭化疗候选药物,专门用于脑癌治疗。
NeOnc Technologies获得美国食品药品监督管理局(FDA)授权,将推进Neo212的二期临床试验。Neo212是一款首创的口服化学共轭化疗候选药物,专门用于脑癌治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.